---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of HPV-Positive Cancer(s)"
date: 2026-02-05 18:56:54 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-20487
original_published: 2023-09-21 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of HPV-Positive Cancer(s)

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 21, 2023 00:00 UTC
**Document Number:** 2023-20487

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Scarlet TCR, Inc. ("Scarlet"), presently headquartered in Kingston, New Jersey.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/21/2023-20487/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-engineered-t)
- API: https://www.federalregister.gov/api/v1/documents/2023-20487

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
